guoguo
Lv1
30 积分
2021-10-15 加入
-
Consensus on management of chronic urticaria using anti-immunoglobulin E therapy (omalizumab)
2个月前
已关闭
-
Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study
2个月前
已完结
-
Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study
2个月前
已完结
-
[Chinese expert consensus on the use of Omalizumab in allergic asthma (2021 version)]
3个月前
已完结
-
Topoisomerase I inhibitors: camptothecins and beyond
3个月前
已完结
-
Camptothecin: current perspectives
3个月前
已完结
-
Advances in Ovarian Cancer Care and Unmet Treatment Needs for Patients With Platinum Resistance
4个月前
已完结
-
Efficacy of Metronomic Oral Vinorelbine, Cyclophosphamide, and Capecitabine vs Weekly Intravenous Paclitaxel in Patients With Estrogen Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer
5个月前
已关闭
-
Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial
8个月前
已完结
-
Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study
11个月前
已完结